Semaphorin 7A (SEMA7A) is a GPI-linked semaphorin that can be released from cell membranes into interstitial fluid and has been reported to have pro-tumourigenic effects in BC, influencing tumour progression, lymphangiogenesis and drug resistance. This evidence concerns the gene SEMA7A and breast cancer.